Actively Recruiting
Study Evaluating the Safety and Effects of PF-08098488 in Adults with Advanced Solid Tumors Including Lung, Pancreatic, and Gastrointestinal Cancers
Led by Pfizer · Updated on 2026-11-03
280
Participants Needed
4
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the safety and effects of a medicine called PF-08098488 in adults with advanced solid tumors, including non-small cell lung cancer, pancreatic cancer, stomach or gastroesophageal junction cancer, and esophageal cancer. These cancers cannot be removed by surgery or have spread to other parts of the body. The study aims to understand how PF-08098488 behaves in the body and its potential as a treatment option. All participants will receive PF-08098488 through an intravenous infusion at the study clinic. The study has different parts where participants receive various doses and schedules of the medicine to find the safest and most effective dose. Participants may continue treatment as long as their cancer does not worsen and they tolerate the medicine. The study includes a screening period of up to 28 days before treatment begins. During the study, participants will have regular clinic visits for treatment and health assessments, including scans to monitor their cancer and blood tests. When possible, tumor tissue samples will be collected. After treatment ends, there will be a follow-up visit about one month later, and then participants will be contacted every 12 weeks to check their health. Researchers will measure safety through adverse events and evaluate cancer response and survival over time.
CONDITIONS
Brief Title
A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.
Research Team
P
Pfizer CT.gov Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here